Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with
immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational
panel of experts in medical oncology, dermatology, gastroenterology, rheumatology,
pulmonology, endocrinology, urology, neurology, hematology, emergency medicine,
nursing, trialist, and advocacy was convened to develop the clinical practice guideline …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated
with immune checkpoint inhibitor (ICPi) therapy. METHODS A multidisciplinary panel of
medical oncology, dermatology, gastroenterology, rheumatology, pulmonology,
endocrinology, neurology, hematology, emergency medicine, nursing, trialists, and
advocacy experts was convened to update the guideline. Guideline development involved a …